Healthcare

ImmunityBio is navigating a stark divide. While its commercial engine, driven by the cancer drug Anktiva, is firing on all...

The stock of telehealth provider Hims & Hers has been under significant pressure, trading roughly 40 percent below its level...

Positive clinical results for a late-stage cancer drug candidate have strengthened BioNTech's strategic pivot away from its pandemic-era business. The...

NurExone Biologic has taken a significant step in its US expansion strategy by forming a new alliance. The company's subsidiary,...

Hydreight Technologies is accelerating the growth of its digital health platform through a dual focus on technological advancement and strategic...

Market confidence in BioNTech is being tested as analysts from prominent firms revise their outlooks downward. Leerink Partners has taken...

Medical technology giant Abbott Laboratories has made a decisive strategic pivot, solidifying its position in the high-growth field of precision...

Following a period of aggressive expansion, Bruker is now entering a critical phase where execution is paramount. The company's recent...

Sangamo Therapeutics finds itself navigating a complex landscape of operational progress against a backdrop of challenging financial performance. Recent developments...

Carl Zeiss Meditec is showcasing its technological prowess on a major stage, even as the company navigates a period of...